Posted by Michael Wonder on 06 Nov 2021
Novavax files COVID-19 vaccine for provisional approval in New Zealand
3 November 2021 - Submission to New Zealand's Medsafe marks the first protein-based COVID-19 vaccine submitted for authorisation to regulatory authorities in New Zealand.
Novavax today announced the company has filed for provisional approval of the vaccine to the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).
